文献速递心胸血管麻醉

全球体外循环调查:泵预充实践与抗凝差异

Pump Priming Practices and Anticoagulation in Cardiac Surgery: Results From the Global Cardiopulmonary Bypass Survey.
PubMed 文献 · Anesth Analg · 2017-01-01

该 survey 通过互联网问卷在 2015 年 6 月至 2016 年 5 月调查成人心脏麻醉医生,分析 923 份回复,发现全球多数受访者认为活化凝血时间低于 400 秒不安全(92.5%),晶体液单独预充最常见(38.1%),但部分实践存在区域差异。

要点

  • 全球 92.5% 受访者认为体外循环中活化凝血时间低于 400 秒不安全。
  • 晶体液单独预充是全球最常见方案(38.1%),晶体联合胶体也较常见(23.8%)。
  • 逆行自体预充使用率为 17.9%,肝素是最常用预充添加剂(43.0%)。

核心结论

  • 区域间体外循环技术在泵预充和抗凝实践上存在某些具体差异。
  • 这些差异对患者结局的意义尚不明确,需进一步研究。

研究设计与样本

  • 16 题互联网问卷由多个区域专业学会分发,目标人群为成人心脏麻醉医生。
  • 调查开放时间为 2015 年 6 月至 2016 年 5 月,共分析 923 份回复。
  • 欧洲、北美、澳大利亚/新西兰和南美的估计回复率分别为 19.77%、8.06%、16.30% 和 1.68%。

主要发现

  • 全球多数受访者认为活化凝血时间低于 400 秒不安全(92.5%)。
  • 晶体液单独预充是最常见方案(38.1%),晶体联合胶体也较流行(23.8%)。
  • 逆行自体预充使用率为 17.9%。
  • 肝素是最常用预充添加剂(43.0%),其次是甘露醇(35.2%)。
  • 部分类别内部存在差异,反映区域实践不同。

关键数值与推荐

  • 活化凝血时间低于 400 秒被认为不安全(92.5% 受访者)。
  • 晶体液单独预充占 38.1%,晶体联合胶体占 23.8%。
  • 逆行自体预充使用率 17.9%,肝素预充添加剂使用率 43.0%,甘露醇 35.2%。

临床怎么用

  • 了解本区域预充和抗凝实践与全球常见做法的差异。
  • 关注活化凝血时间管理,多数受访者以低于 400 秒为不安全。
  • 预充选择可参考晶体液单独或联合胶体的常见模式。

局限性

  • 区域回复率差异大,南美回复率仅 1.68%。
  • 调查基于问卷,未报告患者结局数据。
  • 实践差异对患者结局的意义尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regional patterns of practice in cardiopulmonary bypass remain poorly understood with conflicting evidence regarding the best choices in pump priming preferences with respect to colloid and crystalloid and different types of fluid within these categories. In light of the variation in the literature, we hypothesized there would be considerable regional differences in cardiopulmonary bypass practice, particularly with respect to the type of fluid used to prime the extracorporeal circuit. METHODS: A 16-question, Internet-based survey was distributed by various regional specialist societies, targeting adult cardiac anesthesiologists. One question was directly relevant to activated clotting time and 5 concerned pump priming choices with respect to crystalloid and colloid types and additives. The remaining questions concerned cardioplegia choices. The survey remained open from June 2015 to May 2016. RESULTS: A total of 923 responses were analyzed. Estimated response rates from Europe, North America, Australia/New Zealand, and South America were 19.77%, 8.06%, 16.30%, and 1.68%, respectively. The majority of respondents worldwide considered an activated clotting time of <400 seconds as unsafe for bypass (92.5%). Crystalloid as a sole fluid type remains the most common priming solution worldwide (38.1%) although combinations with colloid (23.8%) were also popular. Retrograde autologous priming was used by 17.9% of respondents. Heparin was the most frequently used prime additive (43.0%) followed by mannitol (35.2%). Variation was demonstrated within some of these categories reflective of differences in regional practices. CONCLUSIONS: Differences exist in some specific areas between regional cardiopulmonary bypass techniques with respect to pump priming and anticoagulation practices. The significance of these differences with respect to patient outcome is uncertain and requires further study.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Miles LF, Coulson TG, Galhardo C, et al. Pump Priming Practices and Anticoagulation in Cardiac Surgery: Results From the Global Cardiopulmonary Bypass Survey. Anesth Analg. 2017. PMID: 28614119. doi:10.1213/ANE.0000000000002052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。